All In Biotech

Drug Trial Radar · NCT04699032

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Renal Function.

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Dec 8, 2020

Primary completion

Jul 5, 2021

Study completion Jul 5, 2021

Sponsor

Lead sponsor
VectivBio AGIndustry
Sponsor type
Industry
First posted
Jan 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study of pharmacokinetics and safety of apraglutide in participants with normal and impaired kidney function.

Conditions

  • Chronic Kidney Disease

Interventions

  • ApraglutideDrug

    Single dose of apraglutide 5 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of ApraglutideTime frame: 5 minutes pre-dose up to 240 hours after dosing on Day 1
  2. Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of ApraglutideTime frame: 5 minutes pre-dose up to 240 hours after dosing on Day 1

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orlando Clinical Research Center

    Orlando, Florida

  • Prism Clinical Research, Inc.

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.